Drukarnia.BLOG
Section 340B

Section 340B shapes how many safety net hospitals buy outpatient drugs. Yet many leaders know it only as a discount. This article explains what Section 340B does, who qualifies, and how to protect your savings. Hospitals that understand the rules keep more money for patient care. They also avoid costly mistakes that quietly drain budgets.

What Is Section 340B?

Section 340B is part of the Public Health Service Act. Its official title is Limitation on Prices of Drugs Purchased by Covered Entities. Congress passed it through Section 602 of the Veterans Health Care Act of 1992.

The law rests on a simple bargain. Manufacturers that want Medicaid and Medicare Part B coverage agree to sell outpatient drugs to safety net providers at a capped price. The Health Resources and Services Administration (HRSA) runs the 340B Drug Pricing Program day to day.

How the Ceiling Price Works

HRSA calculates the 340B ceiling price every quarter. The formula is simple. Take the Average Manufacturer Price (AMP) and subtract the Unit Rebate Amount (URA). The URA is at least 23.1 percent for most brand-name drugs and at least 13 percent for generic and over-the-counter drugs.

Manufacturers report new pricing data each quarter. So the discount your hospital sees on one drug can shift from one quarter to the next.

The Prime Vendor Program Adds Buying Power

The law also created the Prime Vendor Program. Apexus has run it since 2004. Participating entities negotiate sub-ceiling prices as a group instead of facing manufacturers alone. Joining is optional. Still, most hospitals use it because smaller facilities gain the same negotiating leverage as large health systems.

Who Counts as 340B Covered Entities?

Section 340B(a)(4) names the eligible 340B covered entities. They fall into two groups.

  • Hospital-based entities: disproportionate share hospitals, critical access hospitals, sole community hospitals, rural referral centers, children's hospitals, and free-standing cancer hospitals

  • Non-hospital entities: federally qualified health centers, Ryan White grantees, Title X clinics, hemophilia treatment centers, and other federally funded clinics

Each type follows its own path. Some hospitals must meet Medicare payer mix thresholds. Critical access hospitals face no such requirement. Eligibility is never a one-time event. Entities must recertify every year and tell HRSA when their status changes.

A Quick Roadmap for Participation

Once eligibility is confirmed, participation follows six steps. Skip one, and compliance problems follow.

  • Register your entity during the quarterly HRSA window and receive a 340B identification number.

  • Enroll outpatient facilities and contract pharmacies that will dispense 340B drugs.

  • Purchase covered outpatient drugs at or below the ceiling price through an authorized distributor.

  • Track patient eligibility to prevent diversion.

  • Reconcile Medicaid billing to prevent duplicate discounts.

  • Recertify every year and keep OPAIS records current.

Real 340B Program Benefits Go Beyond a Lower Invoice

A well-run program delivers more than cheaper drugs. Here is what covered entities typically gain:

  • Lower drug acquisition costs that free up budget for staff and equipment

  • Wider patient reach for low-income and uninsured patients

  • Access to manufacturer discretionary discounts on orphan drugs

  • Organized records that cut audit preparation time

Strong 340B hospital savings keep service lines open and staffing steady. Every saved dollar returns to patient care.

The Orphan Drug Twist

Section 340B(e) excludes drugs designated for rare diseases from mandatory 340B pricing for certain hospital types. A manufacturer may still choose to offer a discount, but it does so voluntarily.

Rare disease therapies often rank among the costliest items on a pharmacy budget. Their discount status depends on manufacturer discretion, and it can change every quarter. A hospital that does not track those changes may leave savings unclaimed without knowing it. That is why quarterly tracking matters so much.

Know the 340B Compliance Requirements

Savings only last when compliance holds. HRSA and manufacturers can both audit a covered entity, often with little notice. Make sure your team can check off each duty:

  • Keep Office of Pharmacy Affairs Information System (OPAIS) records current

  • Register every outpatient site and contract pharmacy before purchasing

  • Recertify each year

  • Prevent diversion of 340B drugs to ineligible patients

  • Prevent duplicate discounts on Medicaid claims

  • Maintain audit-ready documentation

These 340B compliance requirements protect a program that rewards careful management.

Turn Knowledge Into Savings

Rules and manufacturer policies change often, so confirm current details with HRSA. Many hospitals also want an expert partner for the orphan drug piece.

Dr. Lisa Nezneski, PharmD, BCPS, has spent more than 40 years in healthcare. For the last 11 years, she has focused on 340B orphan drugs. Her work has helped hospitals capture over $500 million in orphan drug savings. 340B Orphan Drug Solutions builds custom orphan drug lists, integrates with split billing software, and delivers quarterly updates. Their approach keeps your team focused on patients instead of spreadsheets.

Ready to find your hidden savings? Book a call with 340B Orphan Drug Solutions today.

Articles about local business and interesting people:

Share your ideas in a new publication.
We are waiting for your longread!
340B Orphan Drug Solutions

340B Orphan Drug Solutions

@j49ZVGb7Fb0bWZ9

3Longreads
41Views
On Drukarnia since August 13

More from the author

You may also be interested in:

Comments (0)

Support the author first.
Write a comment!

You may also be interested in: